Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS

NCT01121588 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01121588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01121588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
March 22, 2011
Completion date
September 7, 2023
Enrollment
44 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms malignant